Ironwood Pharmaceuticals Enhances GI Care with Strategic Conference Participation and Innovative Therapies

Ironwood Pharmaceuticals Advances Gastrointestinal Care with Strategic Engagement

Ironwood Pharmaceuticals, Inc. continues to solidify its position as a leader in gastrointestinal (GI) healthcare with its upcoming participation in the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024. The event, taking place at the Lotte New York Palace, offers a platform for Ironwood’s management to engage with industry stakeholders and discuss the company's innovative approach to treating GI diseases. This fireside chat, scheduled for 12:30 p.m. ET, will be accessible via a live webcast, allowing a broader audience to gain insights into Ironwood's strategic direction and advancements in treatment modalities. Following the event, a replay will be made available, ensuring continued access to the discussion.

Ironwood Pharmaceuticals, founded in 1998 and headquartered in Boston with operations in Basel, Switzerland, is dedicated to redefining standards of care for GI diseases. The company is best known for its flagship product, LINZESS® (linaclotide), which leads the U.S. prescription market for conditions such as irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). LINZESS is also approved for use in pediatric patients aged 6-17, showcasing Ironwood's commitment to addressing a wide range of patient needs. The company’s efforts in research and development are driven by a focus on alleviating the burdens associated with GI disorders, emphasizing patient-centered innovation.

In addition to LINZESS, Ironwood is advancing its pipeline with apraglutide, a next-generation, long-acting synthetic GLP-2 analog targeting rare GI diseases, including short bowel syndrome with intestinal failure (SBS-IF). This strategic focus on both established and emerging therapies reflects Ironwood's commitment to addressing significant unmet medical needs within the GI space. As the company continues to innovate, it remains dedicated to prioritizing patient needs, ultimately aiming to enhance treatment outcomes and improve the quality of life for individuals suffering from gastrointestinal disorders.

Ironwood Pharmaceuticals encourages stakeholders and interested parties to stay informed about its developments by visiting its website and following the company on social media platforms, including X and LinkedIn. This proactive communication strategy underscores Ironwood's commitment to transparency and engagement with the broader healthcare community, as it strives to lead advancements in gastrointestinal care.